I. MODIFIED AGREEMENTS |
|||
Biotech Co.* | Pharma Co. | Change from original agreement | Terms/Details (Date) |
| | |||
3-Dimensional Pharmaceuticals | Centocor Inc. and Johnson & Johnson Pharmaceutical Research and Development LLC (units of Johnson & Johnson) | Extended thrombin collaboration through December | 3DP will receive about $1.4M in additional research funding and will continue to be eligible for milestone payments and royalties on sales of any products marketed under the agreement; the original agreement in December 2000 granted worldwide rights to 3DP's orally active, direct thrombin inhibitor program to Centocor (2/4) |
Cerep SA* | Sanofi- Synthelabo (France) | Renewed drug discovery collaboration in an undisclosed therapeutic area | Cerep plans to provide Sanofi with a major lead, plus secondary chemical compounds, for each of the four targets it is screening (2/19**) |
Cetek Corp.* | Johnson & Johnson Pharmaceutical Research & Development LLC (unit of Johnson & Johnson) | Extended agreement to use Cetek's capillary electrophoresis screening technology | Cetek will develop CE Assays for the J&J division and screen against compound libraries provided by the division; Cetek will receive an up-front payment and screening fees; it could receive milestone payments (1/13) |
Ciphergen | Pfizer Inc. | Expanded collaboration to include studies designed to discover protein biomarkers from human serum that provide early detection of chronic obstructive pulmonary disease vs. healthy individuals | The studies will be conducted at Ciphergen's Biomarker Discovery Center in Copenhagen, Denmark (1/28) |
Corixa Corp. | GlaxoSmithKline Biologicals (unit of GlaxoSmithKline) | Amended collaboration that gives Corixa the rights to therapies for prostate and breast cancer | Corixa will pay up to $32M for proof-of- principle trials on the two vaccines before GSK Biologicals decides whether it wants to buy back the worldwide exclusive licenses from Corixa; if the buyback hap- pens, Corixa could participate in further development and share in U.S. promotion rights (1/30) |
Entelos Inc.* | NV Organon (the Netherlands) | Extended collaboration | Organon will provide up-front fees, milestones and royalties on the sale of immunological and inflammatory drugs (12/3) |
Eos | Aventis Pasteur | Exercised option agreement to develop up to five targets discovered by Eos | Aventis has worldwide rights to develop and commercialize the targets; Eos got an up-front fee on signing the agreement, and will receive funding of research and development; Aventis will provide milestone payments plus royalties on any products that come out of the deal (1/13) |
Gene Logic | Takeda Chemical Industries Ltd. | Expanded GeneExpress subscription agreement | Takeda gains access to the complete Bio- Express dataset, allowing Takeda research- ers to assess the full range of normal and diseased human tissues, animal and cell lines and associated clinical annotations within BioExpress; Takeda will continue to use the complete ToxExpress Predictive System (2/18) |
Genome | Wyeth | Extended drug discovery research alliance to develop therapeutics to prevent and treat osteoporosis | The extension is expected to last through December 2003, with total payments to Genome Therapeutics possibly reaching $118M, excluding royalties (12/30) |
GlycoDesign | Seikagaku | Modified collaboration | The inhibitors are being developed as oral anti-inflammatory drugs; under the new deal, GlycoDesign licensed to Seikagaku exclusive Japanese rights to GlycoDesign's Core 2 assay system for internal research and development purposes, and would receive royalties on products resulting from the research (1/31) |
GTC | Merrimack Pharmaceuticals Inc. | Expanded relationship | The original agreement was for GTC to produce rhAFP in the milk of transgenic goats (1/3) |
Icagen Inc.* | Bristol-Myers | Renewed research and development agreement for the discovery and development of small-molecule drugs targeting a specific ion channel involved in atrial fibrillation | The renewal provides for continued re- search and development funding by BMS (12/20) |
Innogenetics | Solvay | Renewed research collaboration to provide candidate drug targets | The five-year-old partnership is being extended three years, during which both parties will complete work on previously discovered targets as well as explore new ones (1/28) |
Kosan | Johnson & Johnson Pharmaceutical Research and Development LLC | Extended collaboration | Marketing and sales of any resulting drugs would be undertaken by Ortho-McNeil; the collaboration is extended until Dec. 28 (1/14) |
Lexicon | Boehringer Ingelheim Pharmaceuticals Inc. | Expanded OmniBank Universal agreement | Boehringer will continue its access to Lexicon's OmniBank library through February 2004 (3/20) |
Lexicon | Johnson & Johnson Pharmaceutical Research & Development LLC (unit of Johnson & Johnson) | Extended agreement for OmniBank | The J&J unit will continue its access to Lexicon's OmniBank library through December; it also will continue to have access to gene knockouts generated under Lexicon's gene targeting technologies with genetic alterations directed at drug targets of interest and access to drug target validation data generated by Lexicon for specified targets (1/8) |
Ligand | Royalty Pharma Management LLC | Expanded selective estrogen receptor modulator (SERM) royalty agreement for Ligand's approved cancer drug, Targretin | Royalty Pharma exercised an expanded option agreeing to pay Ligand about $6.8M for 0.1875% of future sales of three SERM products now in Phase III development, and for 1% of worldwide sales of Targretin capsules through 2016 (1/7) |
Lynx | Takara Bio Inc. | Expanded technology licensing agreement for Lynx's Megaclone, Megasort and Massively Parallel Signature Sequencing, or MPSS, technologies | Takara accelerated its technology access fee payments to Lynx and its equity purchases of Lynx common stock; the amended license provides Takara with the right in Japan, Korea, China and Taiwan to use Megasort, Megaclone and MPSS (1/9) |
MindGenix | H. Lundbeck A/S | Expanded collaboration to test compounds for the treatment of Alzheimer's disease in MindGenix's relevant model of the disease | The APP/PSI transgenic mouse model used in the platform developed by MindGenix demonstrates behavioral abnormalities and other hallmark features of Alzheimer's neuropathology (1/31) |
Oxford | Pfizer Inc. | Expanded contract agreement for Oxford to provide additional proteomics services | The companies have been working together since 1998 in a collaboration to discover biomarkers and drug development targets in Alzheimer's disease, arteriosclerosis and other disease targets and indications; the area of research and other terms of the new agreement were not disclosed (1/7) |
Pharmacopeia | AstraZeneca | Extended research collaboration shifting efforts from the generation of screening libraries to a drug discovery collaboration to identify promising small-molecule lead compounds against an AstraZeneca drug target | Pharmacopeia will provide its small-molecule drug discovery expertise in return for research funding, potential milestone payments and royalties on any resulting drugs (2/10) |
Sequitur Inc.* | Bristol-Myers | Extended antisense-based agreement | Sequitur will perform biological screening assays and provide Bristol-Myers with RNAi for use in target validation studies; the deal is extended for another year (3/3) |
Thuris Corp.* | Sigma-Tau Industrie Farmaceutiche Riunite | Expanded research collaboration to develop compounds to combat brain inflammation | Thuris is broadening experiments into living animals; financial terms were not disclosed (3/3) |
Vertex | Eli Lilly and Co. | Restructured agreement centered on hepatitic C viral protease inhibitors | Vertex will develop and commercialize VX-950, and has obtained worldwide rights to compounds identified during the collaboration; Lilly will retain a financial interest in VX-950 and other HCV protease compounds through royalties on future net product sales (1/3) |
Viragen Inc. | Laboratorios Pisa | Renewed and extended agreement providing Laboratorios Pisa with the exclusive rights to distribute Multiferon in Mexico | The agreement is extended by 10 years (1/31) |
II. TERMINATED AGREEMENTS |
|||
Corixa Corp. | Japan Tobacco | Terminated agreement for certain rights to a lung cancer vaccine program | Japan Tobacco decided to drop the program as part of the company's restructuring efforts; Corixa reacquired rights in North America and several other countries; Japan Tobacco will retain rights in Japan (2/5) |
Cytogen | Draximage Inc. | Terminated license and distribution agreement and product manufacturing and supply agreement for Draxis' BrachySeed I-125 and BrachySeed Pd-103 products | Cytogen terminated the agreement as a result of Draxis' failure to consistently supply the BrachySeed products at quantities, activity levels and schedules amenable to commercial sales; Draximage disputed Cytogen's claims and said it was exercising its rights to terminate Cytogen's exclusivity with regard to the marketing and distribution of BrachySeed implants in the U.S. (1/27) |
De Novo | F. Hoffmann-La | Completed technology development collaboration with the creation of SkelGen II, a chemoinformatics platform to accelerate drug discovery | De Novo retains full ownership and commercialization rights to SkelGen, and granted a limited license to Roche forinternal drug discovery (2/18) |
GlycoGenesys | Elan Corp. | Terminated joint venture, SafeScience Newco Ltd. | GlycoGenesys will acquire all of Elan's interest in their oncology joint venture in exchange for a royalty interest on certain future revenues related to GCS-100, a cancer product (12/19) |
ImmunoGen | GlaxoSmithKline | Terminated development agreement for cantuzumab mertansine | ImmunoGen regains all rights to the tumor-activated prodrug compound it developed; GSK wanted to renegotiate the product license agreement in order to take the compound into Phase II studies, but the companies could not come to an agreement (1/24) |
Incara | Elan Corp. | Terminated option for an affiliate of Elan to license Incara's catalytic antioxidant compounds for use in combination with cancer radiation treatment | Incara regains full rights to the com- pounds (1/15) |
Isis | Merck & Co. | Terminated agreement for rights to Isis' preclinical Type II diabetes antisense candidate, ISIS 113715 | Isis regains all rights to the candidate; the agreement ended due to the slow progress of taking the product into the clinic (12/23) |
Nastech Pharmaceutical | Pharmacia Corp. | Terminated agreement for a sexual dysfunction product | Nastech reacquires all development and marketing rights to intranasal apomorphine to treat erectile dysfunction and female sexual dysfunction; the terminated agreement results from a Federal Trade Commission investigation of the pending merger between Pfizer Inc. and Pharmacia (1/27) |
| |
|||
Notes: |
|||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. |
|||
* Private companies are indicated with an asterisk. |
|||
** Denotes the date the item ran in BioWorld International. |
|||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. |
|||
AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange |
|||
